Omeprazole controlled release - AGI Therapeutics

Drug Profile

Omeprazole controlled release - AGI Therapeutics

Alternative Names: AGI-010; Chronab omeprazole

Latest Information Update: 08 Jun 2015

Price : $50

At a glance

  • Originator AGI Therapeutics
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Barrett's oesophagus; Gastro-oesophageal reflux

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Jun 2015 Discontinued - Phase-II for Gastro-oesophageal reflux in Canada (PO)
  • 14 Aug 2009 Axcan Pharma terminates its licence for AGI Therapeutics' controlled-release omeprazole in North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top